Competition outside the diabetes area for SGLT-2 inhibitors will further expand this year Following heart failure, this time it is kidney disease. Following AstraZeneca's Forxiga, Lilly and Boehringer Ingelheim's Jardiance also secured indications for chronic kidney disease, and competition is intensifying. In terms of speed, Forxiga is ahead. Forxiga entered the approval process in major countries, including Korea, immediately after approval by the US FDA in April, and added indications for chronic kidney disease in Korea and Europe in August last year. However, insurance benefits have not yet been applied. Boehringer Ingelheim submitted an application for US FDA approval last month. If US approval is completed withi